MedTrace Logo

Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing

NCT02104479 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2020-04-20

No results posted yet for this study

Summary

Diagnostic accuracy of biomarker testing (galactomannan (GM), (1

Conditions

  • Invasive Aspergillosis
  • Pleural Effusion
  • Immunosuppression

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Dieter Buchheidt, MD · Universitätsmedizin Mannheim

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02104479 on ClinicalTrials.gov